Placebo [clinicaltrials_resource:NCT00413283/group/E1]
Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Hyperlipidaemia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/100/count/397]Hypoglycaemia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/101/count/401]Hypokalaemia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/102/count/405]Hypomagnesaemia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/103/count/409]Hyponatraemia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/104/count/413]Arthralgia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/105/count/417]Back pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/106/count/421]Bone pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/107/count/425]Joint swelling for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/108/count/429]Muscle fatigue for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/109/count/433]Muscular weakness for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/110/count/437]Musculoskeletal chest pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/111/count/441]Musculoskeletal pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/112/count/445]Myalgia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/113/count/449]Pain in extremity for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/114/count/453]Cancer pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/115/count/457]Amnesia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/116/count/461]Burning sensation for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/117/count/465]Dizziness for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/118/count/469]Headache for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/119/count/473]Hypoaesthesia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/120/count/477]Neuropathy peripheral for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/121/count/481]Paraesthesia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/122/count/485]Syncope for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/123/count/489]Tremor for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/124/count/493]Confusional state for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/125/count/497]Depression for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/126/count/501]Insomnia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/127/count/505]Restlessness for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/128/count/509]Haematuria for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/129/count/513]Nocturia for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/130/count/517]Renal failure for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/131/count/521]Renal pain for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/132/count/525]Urinary incontinence for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/133/count/529]Chronic obstructive pulmonary disease for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/134/count/533]Cough for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/135/count/537]Dyspnoea for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/136/count/541]Epistaxis for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/137/count/545]Haemoptysis for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/138/count/549]Pleural effusion for NCT00413283 for E1 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/139/count/553]
group [clinicaltrials_vocabulary:group]
Placebo [clinicaltrials_resource:NCT00413283/group/E1]
Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Bio2RDF identifier
NCT00413283/group/E1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00413283/group/E1
group id [clinicaltrials_vocabulary:group-id]
description
Participants received a placeb ...... andard institutional practice.
@en
identifier
clinicaltrials_resource:NCT00413283/group/E1
title
Placebo
@en
type
label
Placebo [clinicaltrials_resource:NCT00413283/group/E1]
@en